NPR : News

Filed Under:

New Pill For Rheumatoid Arthritis Gets FDA Nod

In the Election Day scramble you might have missed that Pfizer got a new drug approved for rheumatoid arthritis.

Pfizer expects the twice-a-day pill called Xeljanz will be available in pharmacies later this month.

The drug won't come cheap. The wholesale price will run about $2,000 for a month's supply, the company says.

There are lots of other treatments for rheumatoid arthritis. There's an inexpensive generic pill called methotrexate. And there are some pricier options — Remicade, Enbrel and Humira, to name three — that require a needle.

But this rheumatoid arthritis drug is the first one that works by blocking enzymes called janus kinases. They play a communication role inside the body and are involved in inflammation associated with rheumatoid arthritis.

Pfizer says Xeljanz (say zel-jans) costs less than the two leading brand-name rheumatoid arthritis treatments.

But not a lot less, according to data from health industry analyst Mark Schoenebaum at ISI Group. He figures a year of treatment with Xeljanz would run only $2,000 or so less than treatment with Enbrel or Humira.

Xeljanz is for patients with moderate-to-severe rheumatoid arthritis who either can't tolerate or don't respond to methotrexate, the Food and Drug Administration said.

In a presentation to investors, Schoenbaum wrote that he expected doctors to use the drug "cautiously" and mainly in patients who had failed Enbrel and Humira.

The new drug's instructions come with a boxed warning, the most serious type of safety information required by FDA. Xeljanz carries a risk of serious infections, including tuberculosis and some illnesses that required hospitalization in clinical tests. The drug also raises cholesterol. It was also associated with an increased risk for some cancers.

Pfizer agreed to study those side effects in a long-term study.

Copyright 2012 National Public Radio. To see more, visit http://www.npr.org/.

NPR

Lisa Lucas Takes The Reins At The National Book Foundation

Lucas is the third executive director in the history of the foundation, which runs the National Book Awards. Her priority? Inclusivity: "Everyone is either a reader or a potential reader," she says.
NPR

The Shocking Truth About America's Ethanol Law: It Doesn't Matter (For Now)

Ted Cruz doesn't like the law that requires the use of ethanol in gasoline. So what would happen if it was abolished? The surprising answer: not much, probably.
WAMU 88.5

The Latest on the Military, Political and Humanitarian Crises in Syria

Russia continues airstrikes in Syria. Secretary Kerry meets with world leaders in an attempt to resolve the country’s five-year civil war. A panel joins Diane to discuss the latest on the military, political and humanitarian crises facing Syria.

NPR

Twitter Tries A New Kind Of Timeline By Predicting What May Interest You

Twitter has struggled to attract new users. Its latest effort at rejuvenation is a new kind of timeline that predicts which older posts you might not want to miss and displays them on top.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.